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Aberrant transcriptional repression through chromatin
remodeling and histone deacetylation has been postulated as
the driving force for tumorigenesis. FBI-1 (formerly called
Pokemon) is a member of the POK family of transcriptional
repressors. Recently, FBI-1 was characterized as a critical onco-
genic factor that specifically represses transcription of the
tumor suppressor gene ARF, potentially leading indirectly to
p53 inactivation. Our investigations on transcriptional repres-
sion of the p53 pathway revealed that FBI-1 represses transcrip-
tion of ARF, Hdm2 (human analogue of mouse double minute
oncogene), and p21CIP1 (hereafter indicated as p21) but not of
p53. FBI-1 showed a more potent repressive effect on p21 than
on p53. Our data suggested that FBI-1 is a master controller of
the ARF-Hdm2-p53-p21 pathway, ultimately impinging on cell
cycle arrest factor p21, by inhibiting upstream regulators at the
transcriptional and protein levels. FBI-1 acted as a competitive
transcriptional repressor of p53 and Sp1 and was shown to bind
the proximal Sp1–3 GC-box and the distal p53-responsive ele-
ments ofp21. Repression involveddirect binding competition of
FBI-1with Sp1 andp53. FBI-1 also interactedwith corepressors,
such as mSin3A, NCoR, and SMRT, thereby deacetylating
Ac-H3 andAc-H4 histones at the promoter. FBI-1 caused cellu-
lar transformation, promoted cell cycle proliferation, and signif-
icantly increased the number of cells in S phase. FBI-1 is aber-
rantly overexpressed in many human solid tumors, particularly
in adenocarcinomas and squamous carcinomas. The role of
FBI-1 as amaster controller of the p53 pathway thereforemakes
it an attractive therapeutic target.
The BTB/POZ2 domain, originally identified in Drosophila
melanogaster bric-a`-brac, tramtrack, and broad complex tran-
scription regulators, and in pox virus zinc finger proteins (1, 2),
is an evolutionarily conserved protein-protein interaction
domain. About 1,000 distinct BTB/POZ entries exist in
sequence data bases (3, 4). Among 194 human BTB/POZ
domain regulatory proteins, about 40 proteins are POK pro-
teins. POK proteins consist of an N-terminal POZ domain and
a C-terminal Kru¨ppel-type (C2H2) zinc finger domain. The
C-terminal zinc fingers recognize and bind specific DNA
sequences, and the POZ domain mediates homo- or het-
erodimerization and interactswith other proteins, such as core-
pressors, histone deacetylase, and other transcription factors,
to regulate transcription (2–4).
BTB/POZ domain regulatory proteins have various cellular
regulatory functions. In particular, some of the POK proteins
with aBTB/POZdomain andKru¨ppel-like zinc finger aremajor
determinants in apoptosis (5), development (6, 7), transcription
(8–14), and oncogenesis (8, 11, 15, 16). The oncogenic mem-
bers of the POK family include promyelocytic leukemia zinc
finger (PLZF) (11, 16), BCL-6 (B cell lymphoma-6) (17), and
HIC-1 (hypermethylated in cancer) (18). Another interesting,
newly identified POK transcription factor with proto-onco-
genic activity is FBI-1 (mouse LRF), encoded by the ZBTB7A
gene (also named Pokemon/rat OCZF), which acts as a tran-
scriptional repressor or activator depending on the promoter
context (8, 19–24).
We have been investigating the biological functions of
human FBI-1 (19–22). FBI-1 was originally purified as a tran-
scription factor that binds to the bipartite inducer of short tran-
scripts element of human immunodeficiency virus, type 1, long
terminal repeat and also to the proximal promoter of the
human ADH5/FDH gene (21, 23). FBI-1 stimulates the Tat
activity of human immunodeficiency virus, type 1, long termi-
nal repeat and represses human ADH5/FDH gene expression
by interacting with Sp1 zinc fingers (21, 24).
The mouse counterpart of FBI-1, LRF, coimmunoprecipi-
tates and colocalizes with BCL-6 and is involved in chondro-
genesis and adipogenesis (25–28). The rat homologue of FBI-1,
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OCZF, is a transcriptional repressor and is involved in oste-
oclastogenesis (29). FBI-1 enhances NF-B-mediated tran-
scription through an interaction between the POZ domain of
FBI-1 and the RHD of NF-B (22). It has also been shown that
FBI-1 acts as a transcription regulator in adipocyte differentia-
tion and adipogenesis (27, 28). Maeda et al. (8) colleagues iden-
tified a central role for LRF in oncogenic transformation, in
which it cooperates with several proto-oncogenes and
decreases expression of the tumor suppressor protein p19
(ARF). They also demonstrated that LRF is a key for instructing
early lymphoid progenitors in mice to develop into B lineage
cells by repressing T cell-instructive signals produced by the
cell-fate signal protein,Notch (30). Evenmore recently, we have
shown that FBI-1 represses transcription of the tumor suppres-
sor Rb gene, and we also demonstrated that FBI-1 blocked dif-
ferentiation of mouse C2C12 myoblast cells into myotubes by
repressing transcription of theRb gene (19). Also, we have dem-
onstrated that expression of FASN (fatty-acid synthase), which
is important in palmitate synthesis and cell proliferation in can-
cer cells, is potently activated by FBI-1 in the presence of
SREBP-1 (20).
FBI-1 is overexpressed in some human cancers, adipose tis-
sues isolated from genetically obese mice, and diet-induced
obese mice, and prostate LNCaP cancer cells treated with
androgen (thus growing fast) (8, 20). FBI-1 can stimulate cell
proliferation by repressing expression of tumor suppressors Rb
and ARF, and also by increasing the supply of cell membrane
lipid component palmitate by activating FASN gene expression
(8, 19, 20). FBI-1 overexpression in NIH3T3 cells results in
more lipid accumulation during differentiation. FBI-1 may be
important for adipocyte differentiation, where it may activate
expression of adipogenic genes, including FASN (20, 27, 28).
FBI-1 appears to be critically involved in cell proliferation, prea-
dipocyte differentiation, and adipogenesis.
p21 inhibits the activities of cyclin-cdk2 complexes and is a
major regulator of mammalian cell cycle arrest (31–33). p21 is
primarily regulated at the transcriptional level (Ref. 34 and ref-
erences therein). Whereas induction of p21 leads predomi-
nantly to cell cycle arrest, repression of p21 gene expression
may have a variety of outcomes, including cell proliferation,
depending on the cell context (Refs. 32, 34 and references
therein). p21 gene is a transcriptional target of p53, which acts
on its distal regulatory elements (31) and plays a crucial role in
mediating G1, G2, or S phase growth arrest upon exposure to
DNA-damaging agents (32, 33, 35–37). In addition to p53, a
variety of other factors, including Sp1/Sp3, Smads, AP2, STAT,
BRCA1, E2F-1/E2F-3, and C/EBP and -, activate the tran-
scription of p21 gene (34).
Other major regulators that affect p21 gene expression are
the Sp1 family transcription factors, which bind to the proximal
promoter (38, 39). The Sp1–3 GC-box bound by Sp1 has been
shown to be particularly important; mutation of the site nearly
eliminates transcription, and it also disrupts the synergistic
transcriptional activation by Sp1 and p53 (38). Sp1 can interact
with proteins of the basal transcriptional machinery, as well as
transcription factors, coactivators and corepressors, including
E2F1, FBI-1, GATA, NF-B, p53, Rb, SREBP-1, YY1, p300,
HDAC, BCL-6 interacting corepressor, NCoR, and SMRT.
These interactions and direct binding competition among Sp1
family and Kru¨ppel-like transcription factors are important in
the transcriptional regulation of genes with a GC-box in their
promoters (38–43).
Expression of proto-oncogenic FBI-1 is increased inmultiple
cancers (8, 44). FBI-1 was recently shown to repress the tumor
suppressor gene ARF, which in turn lowers expression of the
tumor suppressor gene p53. FBI-1 overexpression causes onco-
genesis in the thymus, liver, and spleen (8). Because FBI-1 is also
overexpressed in solid tumors, such as cancers of the colon and
bladder, where the normal functions of ARF and p53 are lost (8,
44), it is likely that FBI-1 has additional target genes through
which it exerts its oncogenic activity.
In this study, we investigated whether the ARF-Hdm2-p53-
p21 pathway (referred to as the p53 pathway) (45), an important
element in cell cycle control and oncogenesis, is controlled by
FBI-1; in particular, we focused on the cyclin-dependent kinase
inhibitor p21 gene. Furthermore, we investigated the mecha-
nism and physiological consequence of FBI-1 action. Our
data suggest that FBI-1 is a master regulator of the p53 path-
way and plays a critical role in regulating important biolog-
ical processes controlled by p21 and other members of the
FIGURE 1. FBI-1 represses transcription of the ARF, Hdm2, and p21 genes
of the p53 pathway. A, transcriptional analysis of ARF, Hdm2, p53, and p21
promoters fused with luciferase genes in HeLa cells. B, reverse transcription-
PCR andWestern blot analysis of stable HeLa cells overexpressing FBI-1, GFP,
andLacZ.Overexpressionwas establishedby infectionwith recombinant len-
tiviruses.GAPDH, control. C, reverse transcription-PCR andWestern blot anal-
ysis. Knockdown of FBI-1 mRNA by siRNAs #1 and #2 increases p21 gene
expression. Mock, negative control. GAPDH, positive control siRNA against
GAPDH.
FBI-1, Master Regulator of p53 Pathway
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p53 pathway, such as oncogenic cellular transformation, cell
growth, and proliferation.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Reagents—pGL2-p21-Luc, pGL2-
p21-Luc WT131 bp, and pGL2-p21-Luc WT101 bp were
kindly provided by Dr. Yoshihiro Sowa (Kyoto Perpetual Uni-
versity of Medicine, Japan). Constructions of pcDNA3-FBI-1
and pcDNA3-FBI-1POZ are reported elsewhere (21). Human
p53 cDNA was cloned into pcDNA3.1 (Invitrogen) to prepare
pcDNA3.1-p53. Sp1ZFDBD (amino acids 622–778) and FBI-
1ZFDBD (amino acids 382–490) were prepared by cloning
PCR-amplified cDNA fragments into pGEX4T1. To prepare
GST-POZFBI-1, a cDNA fragment encoding the POZ domain
of FBI-1 was cloned into pGEX4T3. The lentivirusesM1.4-FBI-
1-FLAG, -GFP, or -LacZ were obtained from Vectorcorea
(Korea). The sequences of all the constructs used in this study
were verified.
Various pGL2 promoter-Luc and expression vectors for p53
and FBI-1 were prepared by standard cloning procedures. Var-
ious purified recombinant proteins were prepared from Esche-
richia coli BL21(DE3) transformed with pGEX4T1 protein
expression vectors (Amersham Biosciences).
Primary and secondary antibodies were obtained from
Upstate (Charlottesville, VA), Chemicon (Temecula, CA), Cal-
biochem, Santa Cruz Biotechnology (Santa Cruz, CA), Dako,
Vector Laboratories, and Abcam (Cambridge, UK). Lipo-
fectamine reagents (Invitrogen) were used for transfection.
Buffer recipes, PCR amplification procedures, siRNA
sequences, and primer sequences are available upon request.
Unless otherwise noted, all other chemical reagents were pur-
chased from Sigma.
Cell Culture—HumanosteosarcomaSaos-2 cell lines, lacking
endogenous p53, were purchased fromATCC (Manassas, VA).
Saos-2 cells were cultured in McCoy’s 5A medium containing
15% fetal bovine serum. All other cell lines were cultured in
Dulbecco’s modified Eagles medium containing 10% fetal
bovine serum (Invitrogen). HeLa cells cultured with Polybrene
(8g/ml)were incubated (37 °C, 5%CO2) for 6–8hwith 350l
of 4  107 transducing units/ml LentiM1.4-FLAG-FBI-1
(experimental) or LentiM1.4eGFP and LentiM1.4LacZ (con-
trol). NIH/3T3 cells were infected with His- and Myc-tagged
LentiM1.4-FBI-1 (experimental) or LentiM1.4 (control). Puro-
mycin was used to select stable cells after 2–3 days.
Doxycycline (1 g/ml)-inducible FBI-1-overexpressing cells
were prepared by transfecting mammalian Flp-In T-REx host
HEK293T cells (Invitrogen) with pOG44:pcDNA5/FRT/
TO-FBI-1 plasmid DNA (9:1). Stable FBI-1-overexpressing
cells were selected with hygromycin (300 g/ml) and blasti-
cidin (15 g/ml).
Transcriptional Analysis—pGL2-Hdm2-Luc, pGL2-ARF-
Luc, and pGL2-p53-Luc were prepared by cloning the pro-
moter fragments into pGL2-Luc Basic (Promega, WI). WT
or mutant p21-Luc reporter plasmids, pcDNA3-FBI-1,
pcDNA3.1-p53, and pCMV-LacZ were transiently transfected
into HeLa cells. Luciferase activity, measured at 36 h, was nor-
malized by cotransfected -galactosidase activity or protein
concentration.
Chromatin Immunoprecipitation (ChIP)—A ChIP assay
(Upstate) was used to investigate whether FBI-1 and FRE inter-
act in vivo. SubconfluentHeLa cells and Saos-2 cells were trans-
fected for 48 h with 1 g of pGL2-p21-Luc and 3 g of either
pcDNA3 or pcDNA3-FBI-1-FLAG. HeLa cells and Drosophila
FIGURE 2.FBI-1 represses transcriptionofp21genebyactingon theGC-richproximal promoter.A and B, structures of the threepGL2-p21-Luc constructs
and the two FBI expression constructs used in transcription assays, shown at right. Open circles, Sp1 binding GC-box; open box, POZ domain; numbered open
circles, zinc fingers; arrowhead, nuclear localization sequence. C, transient transcription assays of p21 promoters in HeLa cells.
FBI-1, Master Regulator of p53 Pathway
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SL2 cells were fixed with 1% formaldehyde, washed, lysed with
SDS lysis buffer, and sonicated into DNA fragments of 500–
1000 bp. Rest of ChIP assays was performed as described else-
where (19, 20).
Oligonucleotide primers were designed to amplify the prox-
imal promoter or distal p53-binding region of p21. To examine
whether ectopic FBI-1 altered the acetylation of the histone H3
and H4 tails of nucleosomes at the proximal p21 promoter ele-
ment, we used antibodies specific to Ac-H3 and Ac-H4 and
followed the same procedures described above.
To investigate the binding competition between Sp1 and
FBI-1, SL2 cells were cotransfected with the pGL2-p21-Luc
2.4-kb reporter plasmid, pPac-Sp1 expression vector and
pPac-FBI-1 expression vector (1–4-fold excess). After 36 h, the
SL2 cells were fixed, immunopre-
cipitated, and analyzed as described
above.
Site-directed Mutagenesis—Mu-
tations were introduced into the
p21 proximal promoter sequence
using the QuikChange site-di-
rected mutagenesis kit (Strat-
agene). Amplified mixtures, incu-
bated (37 °C, 1 h) with DpnI, were
used to transformcompetentE. coli.
Constructs were confirmed with an
ABI automatic DNA sequencer
(Ramsey, MN).
siRNA Experiments—siRNAs for
glyceraldehyde-3-phosphate dehy-
drogenase and the three siRNAs of
FBI-1 were designed and purchased
from Ambion (Austin, TX). Twenty
nanograms of each of three FBI-1
siRNAs were transfected into 6 
106 HeLa cells. Total RNA was pre-
pared from control and experimen-
tal HeLa cells expressing FBI-1,
GFP, and LacZ, using TRIzol
(Invitrogen). cDNAs were synthe-
sized using reverse transcription
with 5 g of total RNA, random
hexamer (10 pmol), and 200 units of
Superscript reverse transcriptase II
(Invitrogen).
Electromobility Shift Assays
(EMSA)—EMSAs were performed
as described (21). Binding reactions
were performed at room tempera-
ture for 30min in binding buffer (20
l) with recombinant FBI-1ZFDBD
or Sp1ZFDBD (0.1 g) and labeled
probe (10,000 cpm). Where indi-
cated, antibodies against GST-Tag,
FBI-1, or Sp1 were also added. To
investigate competitive binding
between Sp1 and FBI-1, the probe
was incubated with recombinant
Sp1ZFDBD (75 ng) and increasing amounts of FBI-1 ZFDBD
(75–675 ng).
Western Blot Analysis—Cells were lysed in RIPA buffer, and
extracts (40 g) were separated on a 10% SDS-PAGE. Proteins
were transferred to an Immun-Blot polyvinylidene difluoride
membrane (Bio-Rad) and blocked for 1 h with 5% skim milk.
Blotted membranes were incubated with various primary anti-
bodies diluted 1:2000, followed by horseradish peroxidase-con-
jugated mouse or goat IgG. Protein bands were visualized with
ECL solution (PerkinElmer Life Sciences).
Immunoprecipitation—Doxycycline-induced HEK293Trex-
FBI-1-FLAG cells were washed, centrifuged, and resuspended
in lysis buffer containing protease inhibitors. Cell lysate was
pre-cleared. The supernatant was incubated overnight at 4 °C
FIGURE 3. FBI-1 binds to the proximal FRE or Sp1 GC-box 3 of the p21 promoter, and the element is
functional in transcriptional repression by FBI-1. A, structure of pGL2-p21-Luc WT (131 bp). Open circles,
GC boxes; filled circles, FRE. Sp1–3GC-box and FRE are overlapping. B, EMSAof Sp1–3GC-box (FRE). FBI-1 binds
the FRE, andmutationof the coreGGG3TTT (mFRE) abolishes FBI-1binding.C,EMSAshowing that Sp1ZFDBD
binds to FRE probe. D, EMSA. FBI-1ZFDBD bound the Sp1–3 GC-box but was unable to bind the mSp1–3
GC-box. Sequence alignment of the Sp1 consensus sequence, Sp1–3 GC box, and the mutated Sp1–3 GC box
is shown above. In mSp1–3 GC-box, the core GGG was mutated into TTT. ZFDBD, zinc finger DNA binding
domain. E, ChIP assays in HeLa cells and structures of two endogenous human gene promoters, p21 and
hGLUT2. Arrows, locations of PCR primers used in ChIP assays. Open circle, GC boxes; filled circle, FRE; gDNA,
genomicDNA. F andG, structures of pGL2-p21-LucWT (131 bp) andmutant FRE.Open circles, GC boxes; filled
circles, FRE. Sp1–3 GC-box and FRE are overlapping. Transcriptional assays of pGL2-p21-Luc WT FRE or pGL2-
p21-LucmFRE inHeLa cells and identification of functional FBI-1-binding element (FRE) important in transcrip-
tional repression are shown.
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withM2 anti-FLAG antibody, followed by proteinA-Sepharose
Fast Flow beads. Beads were collected, washed, and resus-
pended in an equal volume of 5 SDS loading buffer. Immuno-
precipitated proteins were separated by SDS-PAGE and ana-
lyzed by Western blot.
FACSAnalysis—Washed and fixedHeLa cellswere stained in
the dark with 50 g/ml propidium iodide in 100 g/ml ribonu-
clease A for 30 min at 37 °C. DNA content, cell cycle profiles,
and forward scatter were analyzed using a FACSCalibur (BD
Biosciences), with emission detection at 488 nm (excitation)
and 575 nm (peak emission). Data were analyzed using ModFit
LT 2.0 (Verity Software House, Inc., ME) and WindMDI 2.8
(Joseph Trotter, Scripps Research Institute, CA).
Colony Foci FormationAssay—HeLa cells (1 105 cells/well)
were transfected with pcDNA3 or pcDNA3-FBI-1 (0.5 g/l).
Transfected cells were cultured for 2weeks, and colonies resist-
ant to G418 (800 g/ml) selection were stained with crystal
violet (0.5% in 20% ethanol).
MTT Assay—Various cell lines were plated to 30–80%
confluence, transfected for various times at 37 °C with FBI-1
siRNA (500 pmol), and incubated for 3 h at 37 °C with 20
l/well MTT (2 mg/ml). Precipitates were dissolved with 1 ml
of dimethyl sulfoxide. Cellular proliferation was determined
from the conversion of MTT to formazan using a SpectraMAX
250 (Molecular Device Co., Sunnyvale, CA) at 570 nm.
BrdUrd Incorporation—Various cell lines were plated at 40%
confluency and transfected for 48 h with 1.68 g of siRNA,
pcDNA3-FBI-1-FLAG, or pcDNA3. Cells were incubated for
4 h in BrdUrd (20 M)-containing Dulbecco’s modified Eagle’s
medium, washed, and fixed. Cells were then permeabilized,
incubated for 2 h with an anti-BrdUrd monoclonal antibody,
washed, and incubated for 1 h with an AlexaFluor 488 goat
anti-mouse IgG secondary antibody. Nuclei were stained with
DAPI for 10 min. HeLa cells were analyzed using a Radiance
2100 laser scanning system (Bio-Rad).
RESULTS
FBI-1 Is a Potent Transcription Repressor of the p53 Pathway—
Because FBI-1 causesmultiple cancers and is aGC-box-binding
transcription factor, we suspected that FBI-1 might regulate
one or more genes of the p53 pathway (45). First, we analyzed
whether four genes (ARF,Hdm2, p53, and p21) of the p53 path-
way were regulated by FBI-1 in HeLa cells cotransfected with
promoter-luciferase gene fusion reporter plasmids (supple-
mental Fig. 1) and an FBI-1 expression vector. FBI-1 potently
repressed ARF, as reported previously (8), and also repressed
Hdm2 and p21 promoters; however, it did not repress p53.
Additionally, overexpression or knockdown of FBI-1 revealed
that FBI-1 is a transcriptional repressor of p21 inHeLa cells and
also inHCT116 cells (Fig. 1,A–C; supplemental Fig. 2,A andB).
FBI-1 Represses the Transcription of Cell Cycle Arrest p21
Gene, and the POZ Domain Is Important for This Repression—
The transcriptional repressions ofARF andHdm2 aremutually
compensatory in the regulation of p53 stability and/or activ-
ity. Because FBI-1 represses transcription of three genes of
the p53 pathway, and its transcriptional regulatory effects
ultimately converge on the regulation of p21 gene expres-
sion, we selected and examined the transcriptional regula-
tion of p21 by FBI-1 in detail. We examined which region of
the p21 promoter and which domain of FBI-1 are important
in transcriptional repression in HeLa cells. FBI-1 repressed
transcription of three different p21 promoter constructs
FIGURE 4. FBI-1 is a GC-box-binding protein that competeswith Sp1 for binding to the FRE or Sp1GC-box 3 of the p21 promoter to repress transcrip-
tion.A, EMSAof Sp1–3GC-box (or FRE) andbinding competition between Sp1ZFDBDand excess FBI-1ZFDBD. ZFDBD, zinc fingerDNAbinding domain. B,ChIP
assays and binding competition between FBI-1 and Sp1 on the p21 promoter (2.4 kb) in Drosophila SL2 cells. SL2 cells were transfected with pGL2-p21-Luc,
Sp1 expression vector, and excess FBI-1 expression vector. Cellswere fixedwith formaldehyde and analyzed for promoter bindingbyChIP. FBI-1 decreases Sp1
binding. C, ChIP assays and binding competition between FBI-1 and Sp1 on the endogenous p21 promoter in human HEK293A cells. Knockdown of endoge-
nous FBI-1 increased Sp1 binding. D, transcriptional assays. Transcriptional activation of pG5–5x(GC box)-Luc by Sp1 is repressed by FBI-1 in HeLa cells. The
GC-box is derived from the well defined Sp1 binding consensus sequence.
FBI-1, Master Regulator of p53 Pathway
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(70–60%), and repression was particularly potent with a
2.4-kb promoter. Deletion of the FBI-1 POZ domain elim-
inated transcriptional repression, suggesting that the POZ
domain is important in transcriptional repression (Fig. 2C).
FBI-1 repressed transcription by acting on the proximal pro-
moter, which has six Sp1-binding GC-boxes. FBI-1 may also
repress transcription by other mechanisms that involve dis-
tal upstream regulatory elements, because FBI-1 repressed
transcription even more potently on constructs with longer
promoter elements. In human colon cancer HCT116 p53/
and p53/ cells, FBI-1 repressed transcription of p53 path-
way genes even more potently and nearly eliminated tran-
scription of p21 (supplemental Fig. 2, A and B).
Identification of a Functional GC-box Regulatory Element in
the p21 Promoter That Is Critical in Transcriptional Repression
by FBI-1—Because FBI-1 is a GC-box-binding transcription
factor (8), we reasoned that FBI-1-binding sites may be pres-
ent on the p21 promoter, and may
even overlap with Sp1-binding
GC-boxes. We found seven poten-
tial FBI-1-binding sites (FREs),
with varying degrees of binding
affinity, located proximal to or
overlapping with six Sp1-binding
sites (data not shown). EMSA and
transcriptional assays revealed
one functionally significant FRE
(5-GCGGGACCC-3), which
overlapped an Sp1–3 GC-box (Fig.
3A). EMSA of Sp1–3 GC-box (or
FRE) showed that FBI-1 binds the
FRE, and mutation of the core
GGG 3 TTT (mFRE) abolished
FBI-1 binding (Fig. 3B). EMSA
also showed that Sp1ZFDBD
bound to the FRE probe (Fig. 3C).
Additional EMSA showed that
FBI-1ZFDBD bound to the Sp1–3
GC-box but was unable to bind to
the mSp1–3 GC-box (Fig. 3D).
Furthermore, ChIP assays of
endogenous p21 in HeLa cells
showed that FBI-1 bound to the
proximal promoter but not to the
control GLUT2 promoter (Fig.
3E). We tested whether the FRE
overlapping the GC-box-3 is func-
tionally significant in transcrip-
tional repression by FBI-1. In
HeLa cells, FBI-1 repressed pGL2-
p21-Luc WT 131 bp but could
not repress transcription on the
mutated (GGG3TTT) promoter,
suggesting that FBI-1 binds to the
FRE and represses transcription in
vivo (Fig. 3, F and G).
FBI-1 Competes with Sp1 to
Repress Transcription—The above
data suggested that FBI-1 and Sp1 might compete with each
other to bind to the GC-rich FRE/GC-box 3 element. Indeed,
EMSA showed that binding of Sp1ZFDBD to the FRE/Sp1–3
GC-box was competed by excess FBI-1ZFDBD in vitro (Fig.
4A). ChIP assays of binding competition between Sp1 and
FBI-1 on the proximal promoter of p21 in Drosophila SL2
cells also showed similar binding competition (Fig. 4B).
Knockdown of FBI-1 mRNA expression in human HEK293A
cells resulted in decreased FBI-1 binding and increased Sp1
binding to the proximal promoter region of endogenous p21
gene (Fig. 4C). Binding competition between these two pro-
teins may be important in the transcriptional repression of
p21. In HeLa cells, ectopic Sp1 increased transcription of the
reporter pG5–5x(GC)-Luc, and FBI-1 repressed transcrip-
tional activation by Sp1, again suggesting a binding compe-
tition not only on the FRE/Sp1–3 box of p21 gene but also on
the canonical Sp1-binding GC-box (Fig. 3G and Fig. 4D).
FIGURE 5. FBI-1 can repress transcription activation of p53-responsive genes by ectopic p53 or by p53
induced by etoposide treatment. A, induction of p53 by etoposide and transcriptional repression of p21 by
FBI-1 inHeLa cells.B, transcriptional activationofp21byectopic p53 is inhibitedby FBI-1 in Saos-2p53/ cells.
C, transcriptional activation of pGL2–6x(p53RE)-Luc by ectopic p53 can be repressed by FBI-1 in Saos-2 cells.
The p53RE is from the distal p53-binding element of p21. D and E, transcriptional activation of pG13-Luc and
pGL2-Hdm(P2)-Luc by ectopic p53 can be repressed by FBI-1 in Saos-2 cells. pG13 contains 13 copies of the
p53-binding element. The human Hdm2 gene promoter contains one p53-responsive element.
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Overall, our data indicate that FBI-1 is a GC-box-binding
transcription factor that can compete with Sp1 and
repress transcription on the FRE/Sp1–3 box that is critical
for p21 transcription.
FBI-1 Can Repress Transcription Activation of p53-respon-
sive Genes by Ectopic p53 or by p53 Induced by Etoposide
Treatment—FBI-1 yielded more potent transcriptional repres-
sion of the p21 promoter containing the longer regulatory
sequence with p53-binding elements (Fig. 2C). FBI-1 inhibited
the regulatory element of p21 that is critical for transcriptional
activation by Sp1 and communication between proximal Sp1
and distal p53 (Fig. 3G). p53 can interact with Sp1 bound on the
Sp1–3GC-box and can potently activate p21 transcription (38).
p53 expression is inducible by DNA damage, such as that
induced by etoposide treatment. Therefore, we investigated
whether FBI-1 could block the transcriptional activation of p21
by etoposide-activated p53 or by ectopic p53 (inHeLa or Saos-2
cells lacking p53). Transcriptional activation by p53 was
repressed by FBI-1 (Fig. 5, A and B; supplemental Fig. 2, C and
D; and supplemental Fig. 3, A and B). Furthermore, transcrip-
tion of the p53-responsive genes pGL2–6x(p53RE)-Luc, pG13-
Luc, and pGL2-Hdm2(P2)-Luc, which contain the p53-binding
elements of p21, canonical p53-binding element, and human
Hdm2, respectively, were also repressed by FBI-1 in HeLa,
HCT116 p53/, and HCT116 p53/ cells (Fig. 5, C–E; sup-
plemental Fig. 2E; and Fig. 3C).
FBI-1 Binds to the p53-binding Elements of p21 andCompetes
with p53 toRepress Transcription—The above data, particularly
Fig. 5, C and D, suggest that FBI-1 may bind directly to p53-
binding elements to repress transcription activation by p53.
EMSA and ChIP assays performed
on the endogenous p21 gene in
HeLa and Saos-2 cells revealed that
FBI-1 binds directly to the two p53-
binding elements in vitro and in
vivo, respectively (Fig. 6, A and B),
and that p53 and FBI-1 compete for
binding to the p53 regulatory ele-
ments (Fig. 6C and supplemental
Fig. 3D). The ChIP assays also
showed that FBI-1 decreased p53
binding, and vice versa, on the p53-
binding elements (Fig. 6C). Alter-
natively, knockdown of FBI-1
increased p53 binding (Fig. 6D).
FBI-1 and p53 Interact Directly
via Their DNA Binding Domains—
FBI-1 and p53 may interact and
mutually affect DNA binding activ-
ities. Coimmunoprecipitation and
Western blot analyses of protein
extracts prepared from stable HEK
293Trex-FLAG-FBI-1 cells showed
that p53 and FBI-1 interact with
each other (Fig. 7A). Furthermore,
GST fusion protein pulldown assays
indicated that the molecular inter-
action between FBI-1 and p53 was
direct and involved the ZFDBD domain of FBI-1 and the p53
polypeptide, each of which contains a DNA binding domain
(Fig. 7, B and C). Interaction between FBI-1 and p53 may affect
their DNA binding activities, as revealed by ChIP assays with
the two p53-binding elements (Fig. 6C).
FBI-1 Interacts with Corepressor-HDAC Complexes to
Deacetylate Proximal Promoter Histones and to Repress Tran-
scription of Cell Cycle Arrest p21 Gene—Although FBI-1 can
repress transcription by competing with Sp1 and p53 for bind-
ing to critical transcriptional regulatory elements, the mecha-
nism by which FBI-1 represses transcription remains unclear.
Our transcription data suggest that the POZ domain is impor-
tant in transcriptional repression (Fig. 2, B and C). Transcrip-
tional repressors such as PLZF and BCL-6 repress transcription
by interacting with corepressors, such as BCL-6 interacting
corepressor, NCoR, mSin3A, and SMRT, via their POZ
domains. Coimmunoprecipitation of nuclear extracts prepared
from HEK293Trex-FLAG-FBI-1 cells showed that FBI-1 inter-
acted with corepressors such as NCoR, SMRT, and mSin3A
(Fig. 8A). Furthermore, class 1–3 HDACs were also present in
the FBI-1-corepressor complexes. Treatment of HeLa cells
cotransfectedwith pGL2-p21-Luc and pcDNA3-FBI-1with the
HDAC inhibitor TSA increased transcription 2-fold (Fig. 8, B
and C). TSA treatment in the presence of FBI-1 did not fully
de-repress transcription to the TSA-treated control level.
Overall, our data suggest that transcriptional repression by
FBI-1 involves a corepressor-HDAC complex and a binding
competition between the activator Sp1 (or p53) and the repres-
sor FBI-1. Using a ChIP assay on HeLa cells, we investigated
whether the FRE/Sp1–3 GC-box-bound FBI-1-corepressor-
FIGURE 6. FBI-1 competes with p53 for binding to the distal p53-binding elements of p21 to block tran-
scriptional activation by p53. A, EMSA showing that FBI-1 binds two distal p53-binding elements. ZFDBD,
recombinant zinc finger DNA binding domain. B, ChIP assay of FBI-1 binding on the endogenous distal p53-
binding elements of p21 in HeLa cells transfectedwith pcDNA3-FLAG-FBI-1.M, DNA sizemarker. C,ChIP assays
and binding competition between FBI-1 and p53 on the distal p53-binding elements of endogenous p21 in
Saos-2 cells. Saos-2 cells were transfected with a p53 expression vector, with or without an FBI-1 expression
vector. Coexpression of p53 and FBI-1 decreases binding of the other.D, ChIP assays showing that knockdown
of endogenous FBI-1 in HEK293A cells increases p53 binding. IP, immunoprecipitation.
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HDAC complex and the distal p53-binding elements could
deacetylate Ac-H3 and Ac-H4 histones bound to the proximal
promoter of endogenous p21. FBI-1 significantly decreased the
acetylation of histones 3 and 4, suggesting that histone deacety-
lation at the proximal promoter is responsible for transcrip-
tional repression by FBI-1 (Fig. 8D).
FBI-1 Causes Cellular Transformation and Promotes Cell
Proliferation—p21, a major regulator of cell cycle arrest, is
potently repressed by FBI-1 at the transcriptional level. There-
fore, FBI-1 may cause cellular transformation and promote cell
cycle progression. HeLa cells transfected with FBI-1 expression
vectors formed substantial numbers of large transformation
foci, suggesting that FBI-1 caused cellular transformation (Fig.
9A). FACS analysis showed that FBI-1 overexpression stimu-
lated cell cycle progression and increased the number of HeLa
cells in S phase (28.9% in control HeLa-LacZ versus 50.5% in
HeLa-FBI-1). Furthermore, the number of cells in G2-M phase
decreased from 19.7 to 1%. Knockdown of endogenous FBI-1
mRNA resulted in a decreased number of cells in S phase and a
concomitant increase in the number of cells in G0-G1 phase
(Fig. 9B). MTT assays also showed that although FBI-1 overex-
pression significantly increased cell viability or growth, FBI-1
knockdown by RNA interference decreased cell viability or
growth (Fig. 9C). Although the percentage of cells incorporat-
ing BrdUrd (as an indicator of cell proliferation) significantly
increased in NIH/3T3 cells and HEK292Trex cells stably
FIGURE 7. Zinc finger DNA binding domain of FBI-1 interacts with p53 via the p53 DNA binding domain (DBD). A, coimmunoprecipitation of FBI-1 and
p53. Lysates prepared from control HEK293Trex cells and stable 293Trex-FLAG-FBI-1 cells were immunoprecipitated (IP) using anti-FLAG M2 antibody beads
and analyzed byWestern blotting (WB) with anti-p53 and anti-FBI-1 antibodies. B andC,GST fusion protein pulldown assays. Recombinant GST, GST-POZFBI-1,
or GST-ZFDBDFBI-1 were incubated with [35S]methionine-labeled p53 or its deleted polypeptides, pulled down, and resolved by 15% SDS-PAGE. The gel was
then exposed to x-ray film.
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expressing FBI-1 (supplemental Fig. 4, B–F), knockdown of
FBI-1 mRNA significantly decreased the number of HeLa cells
incorporating BrdUrd (Fig. 9D). In stable human colon cancer
HCT116 p53/ and p53/ cells overexpressing FBI-1, FBI-1
decreased p21 expression, stimulated cell cycle progression,
and increased the number of cells in S phase, regardless of the
presence of p53. Knockdown of FBI-1 mRNA had the opposite
effect. These effects were more dramatic following etoposide
treatment, when most cells were in S phase and only a few cells
were in G0-G1 phase following FBI-1 overexpression (supple-
mental Fig. 6). Interestingly, FBI-1 expression was decreased by
genotoxic stress, suggesting the possibility of protein degrada-
tion, as was recently reported for BCL-6 (46) (supplemental Fig.
5, A and B).
We analyzed FBI-1 expression in
human solid cancer tissues by
immunochemical staining of tissue
microarrays. Most of the tumors
with positive FBI-1 staining were
adenocarcinomas or squamous car-
cinomas of the stomach, pancreas,
lung, prostate, etc. In particular, of
the 45 colon cancer tissue microar-
ray cores tested, 19 displayed strong
FBI-1 expression in the nucleus of
cancer tissue regions (data not
shown).
DISCUSSION
We have been investigating the
novel biological functions of human
POK protein FBI-1 (19–22), which
is overexpressed in human cancers
and prostate LNCaP cancer cells
treated with androgen (thus grow-
ing fast) (8, 20). Recently, increasing
amounts of information obtained by
us and others suggested that FBI-1
may be critically involved in cell
growth, cell proliferation, oncogen-
esis, and cancer (8, 19, 20).
Maeda et al. (8) identified a cen-
tral role for mouse FBI-1/LRP in
oncogenic transformation, in which
expression of the tumor suppressor
protein, ARF, is decreased. ARF is a
negative regulator of ubiquitin-pro-
tein isopeptide ligase Mdm2, which
participates in the degradation of
p53 by ubiquitin-dependent degra-
dation by the proteasome. The
repression of ARF expression can
stimulate cell proliferation by
decreasing the stability or activity of
p53 via Mdm2.
p53 and NF-B pathways are
intertwined in cellular physiology,
and p53 and NF-B repress the
activities of each other (Ref. 47 and references therein). NF-B
represses p53 stability by directly up-regulating Mdm2. Inter-
estingly, whereas FBI-1 down-regulates p53 expression via
ARF-Mdm2, it also enhances activity of NF-B. The NF-B
pathway is recognized to be the central mediator of immune
response in mammals. NF-B proteins are frequently hyperac-
tive in cancer and inflammatory diseases. NF-B proteins acti-
vate their target genes, which regulate diverse physiological
processes ranging from cell proliferation and invasion to cell
death. There is a strong correlation between constitutively
activeNF-Band chronic inflammation,which in turn is adeter-
minant in the development of many cancers (47). Interestingly,
FBI-1 was shown to increase the transcription of NF-B-respon-
sive genes by dramatically increasing nuclear stay of NF-B (23),
FIGURE8.FBI-1 interactswith corepressors anddeacetylateshistonesAc-H3andAc-H4boundat thep21
proximal promoter. A, coimmunoprecipitation of FBI-1 and corepressors NCoR, SMRT, and mSin3A. Nuclear
extract prepared from HEK293Trex control and stable HEK293Trex-FLAG-FBI-1 cells were coimmunoprecipi-
tated with anti-FLAG M2 antibody. Precipitates were analyzed by Western blot (WB) using antibodies against
FBI-1 and corepressors. Tubulin, control (Con). IP, immunoprecipitated. B, coimmunoprecipitation of FBI-1 and
class 1–3 HDACs. Assays were carried out as in A. C, transcriptional repression by FBI-1 involves HDACs. HeLa
cells were transfectedwith pGL2-p21-Luc, with orwithout an FBI-1 expression vector. Transfected cells treated
with TSA for 30 h before harvest were analyzed for luciferase activity.D,ChIP assays for histonemodification at
the proximal promoter of endogenous p21 using antibodies against Ac-H3 and Ac-H4. HeLa cells were trans-
fected with an FBI-1-FLAG expression plasmid and immunoprecipitated with the antibodies indicated. A his-
togram of the ChIP assays is shown at the right.
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whichmaybe important inprolonged inflammatory reactions and
perhaps in cell proliferation and the development of cancer.
The Rb protein is a tumor suppressor that plays a pivotal role
in the negative control of the cell cycle and tumor progression
(48).We recently demonstrated that FBI-1 could repress tumor
suppressor Rb gene expression, which can reverse the cell cycle
arrest effect of Rb (19). Furthermore, we also showed that FBI-1
plays a critical role in the synthesis of fatty acid palmitate in the
presence of SREBP-1 or -2, master controller of fatty acid syn-
thesis, thereby providingmore cellular lipidmembrane compo-
nents needed for rapid cell proliferation in cancer cells (20).
All the above data suggest that FBI-1 may regulate a set of
genes important in cell growth and proliferation, whichmay be
important in the development of
cancer and cell proliferation of can-
cer cells. We investigated whether
FBI-1 could regulate the p53 path-
way, a key player in cell cycle reg-
ulation. We showed that FBI-1
directly or indirectly represses
expression of ARF, Hdm2, and p21
genes of the p53 pathway (Fig.
10A). Because the repression of
ARF and Hdm2 genes by FBI-1 is
mutually compensatory in terms
of p53 expression, and FBI-1
potently stimulates cell cycle pro-
gression, we reasoned that the
principal target of FBI-1 might be
the cell cycle arrest gene p21. In
addition to blocking or inhibiting
expression of ARF and Hdm2, and
thereby eventually affecting p21
expression via regulating p53
expression, FBI-1 directly inhibits
the critical elements (i.e. proximal
FRE/Sp1–3 GC-box and p53-re-
sponsive elements) for transcrip-
tional repression of p21, each of
which are important in basal and
inducible expression of p21.
In particular, our in-depthmolec-
ular investigation of p21 transcrip-
tion revealed novel features of the
proto-oncogene FBI-1. First, FBI-1
is a GC-box-binding transcription
factor, which can compete with Sp1
for binding to the proximal FRE/
Sp1–3 GC-box. This competitive
binding by FBI-1 inhibits basal tran-
scriptional activation by Sp1 and
abrogates synergistic communica-
tion between Sp1 and p53 bound at
the two distal p53 binding elements.
Second, FBI-1 is a p53-responsive
element-binding protein. It inhibits
p53 through binding competitively
with p53 at p53-responsive ele-
ments or by interacting directly with p53.
We propose amodel for the transcriptional repression of p21
by FBI-1 (Fig. 10). Under normal cellular conditions where p53
levels are low and no FBI-1 is present, p21 is expressed at a low
level and cells proliferate normally. When cells are chal-
lenged with genotoxic stress, the tumor suppressor p53 is
markedly induced and activates transcription of p21 by
interacting with Sp1 bound at the FRE/Sp1–3 GC-box. The
induced p21 arrests cell cycle progression and allows cells to
repair DNA damage. When cells are under genotoxic stress
(and thus have high levels of p53) and FBI-1 expression is
high (as is the case in some cancer tissues or highly prolifer-
ative tissues), FBI-1 represses transcription by directly bind-
FIGURE 9. FBI-1 causes cellular transformation and promotes cell cycle progression and prolifera-
tion. A, foci formation assays. HeLa cells transfected with the FBI-1 expression vector were cultured in
G418 medium and stained with 0.1% crystal violet. B, FACS analysis of cell cycle progression. HeLa cells
stably overexpressing FBI-1 and LacZ were established by lentivirus infection, or HeLa cells transfected
with an siRNA against FBI-1 mRNA were stained with propidium iodide, and cell proliferation was meas-
ured.Mock, transfection without siRNA; N.C., scrambled siRNA negative control. C,MTT assay of HeLa and
stable HeLa-FBI-1 cells grown for 2, 4, or 6 days. Alternatively, MTT assays were performed in HeLa cells
treated with either negative control siRNA or siRNA specific to FBI-1. All assays were performed in tripli-
cate. Error bars are included, but are too tight to see. D, knockdown of FBI-1, and BrdUrd incorporation.
HeLa cells were transfected with control siRNA or three different FBI-1 siRNAs. After transfection, cells
were grown in media containing BrdUrd and analyzed for BrdUrd incorporation as under “Experimental
Procedures.” FITC, fluorescein isothiocyanate; DAPI, 4,6-diamidino-2-phenylindole.
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ing to both the proximal FRE/Sp1–3 GC-box and the distal
p53-binding elements. Although p53 expression is high, it
must compete with FBI-1 to bind to the distal p53-binding
elements. Molecular interactions between p53 and FBI-1 can
also inhibit p53 binding. Because the proximal FRE/Sp1-GC
box is occupied by FBI-1, p53 cannot activate transcription.
The FBI-1-corepressor-HDAC complexes deacetylate his-
tones H3 and H4 at the proximal promoter, thereby repress-
ing transcription of the p21 gene promoter. Cells proliferate
without cell cycle arrest, mutations accumulate, and cells are
likely to undergo oncogenic transformations.
MIZ-1 (Myc-interacting zinc finger protein 1), another inter-
esting POK family protein that binds to the proximal promoter
of p21 gene, is a transcription activator of the p21 gene (49).
c-Myc and BCL-6 were previously shown to repress transcrip-
tion of the p21 gene after being recruited to the p21 promoter
by molecular interaction with MIZ-1 (49, 50). Interestingly,
FBI-1 transcription repressor binds to the element intercalated
between the two juxtaposed MIZ-1-binding elements (49).
Although largely uncharacterized, this complex interaction
among MIZ-1, FBI-1, Sp1 and proximal promoter elements
may also contribute to the transcriptional repression of cell
cycle arrest gene p21.
The molecular mechanism revealed here is quite different
from those of other POK or POK-related proteins such as
BCL-6, PLZF, and PLZF-RAR. BCL-6 is expected to function
by directly binding to specific DNA sequences and suppressing
the transcription of target genes, as reported for DNA damage
sensor ATR gene (ATM- and Rad3-related) (51), PDCD2 gene
(programmed cell death-2) (52), and
p53 gene promoter (53), by EMSA
andChIP. However, with the excep-
tion of the few cases mentioned
above, the molecular action mecha-
nism of true in vivo BCL-6 target-
binding sites remains largely
elusive. BCL-6 controls the tran-
scription of genes lacking a BCL-6-
binding site by an alternative mech-
anism. BCL-6 interacted with the
transcription activator MIZ-1 and,
viaMIZ-1, bound the proximal pro-
moter and suppressed transcription
of the cell cycle arrest gene p21 (50).
Through this repression mecha-
nism, BCL-6 may facilitate the pro-
liferative expansion of germinal
centers during the normal immune
response and, when deregulated,
the pathological expansion of B cell
lymphomas.
Although potential binding sites
for PLZF were identified by CAST
assays (54), and PLZF was shown to
bind to the promoters and repress
transcription of c-Myc and HoxD
genes (55, 56), true in vivo regula-
tory binding sites and the molecular
action mechanism of repression by PLZF remain largely
unknown, as for BCL-6. Although a transcriptional regulatory
mechanism for PLZF-RARwas proposed that involves poten-
tial binding to retinoic acid-response element on the genome
and participation of corepressors andHDACs, the true target of
PLZF-RAR also remains uncharacterized (11, 16). Our
unpublished data3 and ongoing investigation indicate that
PLZF and PLZF-RAR are also potent regulators of cell growth
and proliferation, controlling the p53 pathway in amanner sim-
ilar to that of FBI-1, as characterized in this report. A recent
report by Savage et al. (57) reported that tissues from PLZF-
transgenic mice show significant increases in the ethynyl
deoxyuridine assay for proliferation, and a microarray experi-
ment of PLZF knock-out mice showed elevated expression of
p21 and p53 mRNA, suggesting a cell proliferative effect of
PLZF by expression modulation of the p53 pathway (Gene
Expression Omnibus, www.ncbi.nlm.nih.gov). The molecu-
lar mechanism elucidated in this study for FBI-1 may also
underlie the cell proliferation of hematopoietic cells, or
acute promyelocytic leukemic cells, caused by abnormal
expression of BCL-6, PLZF, and PLZF-RAR.
Overall, the molecular features of FBI-1 revealed in this
investigation may explain how FBI-1 acts as a master control
gene of cellular transformation and cell proliferation by
potently blocking the p53 pathway. Our data should also pro-
vide insight into the regulatory role of POK family transcription
3 W.-I. Choi and M.-W. Hur, unpublished data.
FIGURE 10. FBI-1 is amaster controller of theARF-Hdm2-p53-p21pathway.A,p53pathway and regulation
by FBI-1.3, transcriptional activation; solid linewith, transcriptional repression; solid linewith, transcrip-
tional repression by binding competition with p53;7 , protein-protein interaction;7 with , inhibition of
binding by protein-protein interaction. B,model of transcriptional repression of p21 in three different physio-
logical states. Proto-oncogene FBI-1 attacks the three critical elements (FRE or Sp1–3 GC-box, and two
p5- responsive elements) that are important in basal constitutive and inducible expression. FBI-1 recruits
corepressor-HDAC complexes anddeacetylates histonesAc-H3 andAc-H4 at theproximal promoter to repress
transcription. FBI-1 also interacts with p53 to inhibit p53 binding, and vice versa. Tsp (1), transcription start
site; ZF, zinc finger DNA binding domain.
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regulators in cell growth and proliferation, and potentially in
oncogenesis.
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